RS Investment Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

RS Investment Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$3.38M	Sell	87,958 -770	-0.9%	-$32K	0.03%	289
2016 Q1	$3.38M	Buy	88,728 +24,511	+38%	+$854K	0.03%	284
2015 Q4	$2.82M	Buy	64,217 +6,557	+11%	+$325K	0.03%	279
2015 Q3	$2.35M	Buy	57,660 +18,900	+49%	+$829K	0.02%	290
2015 Q2	$2.07M	Sell	38,760 -251,030	-87%	-$13.3M	0.02%	306
2015 Q1	$17.6M	Buy	289,790 +46,330	+19%	+$2.25M	0.16%	200
2014 Q4	$12.7M	Buy	+243,460	New	+$10.9M	0.11%	227

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

Riverhead Capital Management Wilmington, Delaware $2.71B AUM 2.34% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RS Investment Management's JUNO Position: Q2 2016 in Review

RS Investment Management reduced its Juno Therapeutics, Inc. (JUNO) stake by 0.87% in Q2 2016, selling an estimated $32K and leaving 87,958 shares worth $3.38M. The position accounts for 0.03% of the portfolio, ranked #289.

RS Investment Management first reported a position in JUNO in Q4 2014 and has held it in 7 quarters since. The position peaked at $17.6M in Q1 2015. 170 funds tracked by Wall St. Rank hold JUNO as of Q2 2016.

RS Investment Management held 87,958 shares of Juno Therapeutics, Inc. worth $3.38M as of Q2 2016.
RS Investment Management sold 770 Juno Therapeutics, Inc. shares in Q2 2016, an estimated $32K.
Juno Therapeutics, Inc. made up 0.03% of RS Investment Management's portfolio in Q2 2016, its #289 holding.
RS Investment Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and has held it in 7 quarters since.
RS Investment Management's Juno Therapeutics, Inc. position peaked at $17.6M in Q1 2015.
170 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.